PubMed
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Attie et al., 2013
Healing & RecoveryResearch Only — Development HaltedC
ACE-031
Ramatercept / ActRIIB-Fc
ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.
Observational report only — modeled community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- C
- Experience
- 76
- Activity
- 43
Overall check-ins
Trackers & reports
Overview
About ACE-031
ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.
- Category
- Healing & Recovery
- Regulatory status
- Research Only — Development Halted
- Also known as
- Ramatercept / ActRIIB-Fc
- Self-reports
- 308
Community
What 308 users report
308 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 62% · Mixed 22% · Unfavorable overall 16%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Joint comfort
-149
Recovery
-31
Digestive comfort
-151
Skin appearance
-99
Appetite control
-47
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site reaction
-53
Anxiety
-132
Flushing
-6
Headache
-103
GI discomfort
-48
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 100–200 mcg
Reports span 25–1000 mcg
25–50
4
50–100
14
100–200
18
200–400
9
400–600
6
600–1000
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing32stacking10side effects28ace-03116
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 30% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 68 repeat reporters
Community charts use modeled aggregates when live Supabase snapshots are unavailable.
Research
Cited research (4)
Source
PubMed
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Campbell et al., 2017
PubMed
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig et al., 2022
ClinicalTrials.gov
ACE-031 (ActRIIB-Fc) studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
Tools
Explore more
Explore
More ways to learn about ACE-031 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about ACE-031?
This page summarizes 308 anonymized self-reports from PeptIQ users who track ACE-031, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for ACE-031?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for ACE-031?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is ACE-031 safe to use?
This wiki does not assess safety or recommend use. ACE-031 is listed as Research Only — Development Halted. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of ACE-031?
Research, primarily in animal models, suggests ACE-031 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of ACE-031?
ACE-031 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified ACE-031 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of ACE-031?
The safety and effectiveness of ACE-031 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on ACE-031?
While there are over 200 published studies on ACE-031, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source